Research Alert: CFRA Keeps Buy Rating On Shares Of Abbvie Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $255 from $275, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.0x, justified by the company's improving long-term growth prospects. We lower our 2026 EPS forecast to $14.02 from $14.29 as we adjust our Q1 EPS estimate to $2.63 from $3.05. The company disclosed a new IPR&D and milestone expense of $744M last week related to collaborations, licensing agreements, and asset acquisitions, which will dilute Q1 EPS. We keep our 2026 EPS estimate at $16.13. The company is expected to report Q1 results before market open on April 29, when we expect to get more color on Q1 performance and expectations for the remainder of 2026.

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to $255 from $275, 15.8x our 2026 EPS view. This is above ABBV's 10-year historical forward P/E average of 12.0x, justified by the company's improving long-term growth prospects. We lower our 2026 EPS forecast to $14.02 from $14.29 as we adjust our Q1 EPS estimate to $2.63 from $3.05. The company disclosed a new IPR&D and milestone expense of $744M last week related to collaborations, licensing agreements, and asset acquisitions, which will dilute Q1 EPS. We keep our 2026 EPS estimate at $16.13. The company is expected to report Q1 results before market open on April 29, when we expect to get more color on Q1 performance and expectations for the remainder of 2026.